Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “Merck”

A Personalized Neoantigen Cancer Vaccine in Treatment Naïve, Asymptomatic Patients With IGHV Unmutated CLL.Recruiting
NCT03219450Phase 1Updated May 28, 2026
Sponsor: Dana-Farber Cancer Institute
Lymphocytic Leukemia
United States
BC3195 in Combination With Pembrolizumab in Participants With Locally Advanced or Metastatic Solid TumorsRecruiting
NCT07469774Phase 1, Phase 2Updated May 28, 2026
Sponsor: Biocity Biopharmaceutics Co., Ltd.
Locally Advanced or Metastatic Solid Tumors
China
The Effect on Lipid Profile of Switching to Delstrigo in HIV Positive PatientsTerminated
NCT05289986Phase 4Updated May 28, 2026
Sponsor: Chelsea and Westminster NHS Foundation Trust
Hiv
United Kingdom
Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B/KEYMAKER-U02)Completed
NCT04305054Phase 1, Phase 2Updated May 28, 2026
Sponsor: Merck Sharp & Dohme LLC
Melanoma
United States, Argentina, Australia, Chile, Colombia +9 more
A Substudy of Investigational Agents in Programmed Cell Death-1/Ligand 1 (PD-1/L1) Refractory Locally Advanced or Metastatic Urothelial Carcinoma (mUC) (MK-3475-04A)Recruiting
NCT05562830Phase 1, Phase 2Updated May 27, 2026
Sponsor: Merck Sharp & Dohme LLC
Urothelial Carcinoma
United States, Australia, Canada, Chile, Denmark +6 more
Evolution of the Therapeutic Care in Metastatic Breast Cancer From 2008Recruiting
NCT03275311N/AUpdated May 27, 2026
Sponsor: UNICANCER
Metastatic Breast Cancer
France
A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell CancersRecruiting
NCT05910827Phase 1, Phase 2Updated May 27, 2026
Sponsor: Hummingbird Bioscience
Advanced or Metastatic Squamous Non-Small Cell Lung Cancer · Advanced Head and Neck Squamous Cell Carcinoma · Advanced Esophageal Squamous Cell Carcinoma · Cervical Squamous Cell Carcinoma
Australia, Moldova, Singapore, South Korea, Taiwan
Evolution of the Therapeutic Care in Lung Cancer in France Since 2015 (ESME LC)Recruiting
NCT03848052N/AUpdated May 27, 2026
Sponsor: UNICANCER
Lung Cancer
France
A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)Completed
NCT05064059Phase 3Updated May 26, 2026
Sponsor: Merck Sharp & Dohme LLC
Colorectal Cancer
United States, Australia, Canada, Chile, China +16 more
Substudy 01A: Safety and Efficacy of Opevesostat (MK-5684)-Based Treatment Combinations or Opevesostat Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-01A)Recruiting
NCT06353386Phase 1, Phase 2Updated May 26, 2026
Sponsor: Merck Sharp & Dohme LLC
Prostatic Neoplasms, Castration-Resistant
United States, Australia, Canada, Chile, Colombia +15 more
Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)Active Not Recruiting
NCT04624204Phase 3Updated May 26, 2026
Sponsor: Merck Sharp & Dohme LLC
Small Cell Lung Cancer
United States, Australia, Belgium, Bulgaria, Canada +20 more
Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)Recruiting
NCT06686394Phase 1, Phase 2Updated May 22, 2026
Sponsor: Merck Sharp & Dohme LLC
Breast Neoplasms · Breast Cancer
United States, Canada, Israel, Japan, South Korea +1 more
Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66)Active Not Recruiting
NCT05239741Phase 3Updated May 22, 2026
Sponsor: Merck Sharp & Dohme LLC
Colorectal Neoplasms
China
Pembrolizumab and XL888 in Patients With Advanced Gastrointestinal CancerCompleted
NCT03095781Phase 1Updated May 22, 2026
Sponsor: Emory University
Colorectal Adenocarcinoma · Metastatic Pancreatic Adenocarcinoma · Recurrent Colorectal Carcinoma · Recurrent Pancreatic Carcinoma
United States
A Study of Belzutifan (MK-6482) in Participants With Advanced Clear Cell Renal Cell Carcinoma (MK-6482-018)Completed
NCT04846920Phase 1Updated May 22, 2026
Sponsor: Merck Sharp & Dohme LLC
Carcinoma, Renal Cell
United States
Vaccination With Flt3L, Radiation, and Poly-ICLCCompleted
NCT03789097Phase 1, Phase 2Updated May 22, 2026
Sponsor: Icahn School of Medicine at Mount Sinai
Non-Hodgkin's Lymphoma · Metastatic Breast Cancer · Head and Neck Squamous Cell Carcinoma
United States
Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)Completed
NCT03260894Phase 3Updated May 22, 2026
Sponsor: Incyte Corporation
Renal Cell Carcinoma (RCC)
United States, Australia, Brazil, Canada, Chile +15 more
Multiple Dose Study of MK-2828 in Participants With Type 2 Diabetes (MK-2828-003)Completed
NCT07089784Phase 1Updated May 22, 2026
Sponsor: Merck Sharp & Dohme LLC
Diabetes Mellitus, Type 2
United States
A Study of Mirdametinib in Combination With Palbociclib in People With LiposarcomaRecruiting
NCT06843967Phase 1, Phase 2Updated May 22, 2026
Sponsor: Memorial Sloan Kettering Cancer Center
Well Differentiated Liposarcoma · Dedifferentiated Liposarcoma · Liposarcoma · Myxoid Liposarcoma
United States
EACH: Evaluating Avelumab in Combination With Cetuximab in Head and Neck CancerCompleted
NCT03494322Phase 2Updated May 20, 2026
Sponsor: University College, London
Head and Neck Cancer · Squamous Cell Carcinoma
United Kingdom
Study of Patritumab Deruxtecan Plus Pembrolizumab With Other Anticancer Agents in Participants With High-Risk Early-Stage Triple-Negative or Hormone Receptor-Low Positive/HER-2 Negative Breast Cancer (MK-1022-010, HERTHENA-Breast-03)Recruiting
NCT06797635Phase 2Updated May 20, 2026
Sponsor: Merck Sharp & Dohme LLC
Breast Neoplasms · Breast Cancer
United States, South Korea, Spain, Taiwan
Trial of Pembrolizumab Following Weekly Paclitaxel for Platinum-resistant Ovarian, Fallopian Tube or Peritoneal CancerCompleted
NCT03430700Phase 2Updated May 20, 2026
Sponsor: University College, London
Ovarian Cancer · Fallopian Tube Cancer · Peritoneal Cancer
United Kingdom
A Study of Pembrolizumab And Platinum With Radiotherapy in Cervix CancerTerminated
NCT03144466Phase 1Updated May 20, 2026
Sponsor: Royal Marsden NHS Foundation Trust
Cervix Cancer
United Kingdom
Extension Study of Long-term Safety and Efficacy of Tulisokibart in Participants With Crohn's Disease or Ulcerative Colitis (MK-7240-011)Recruiting
NCT06651281Phase 3Updated May 19, 2026
Sponsor: Merck Sharp & Dohme LLC
Crohn Disease · Colitis, Ulcerative
United States, Czechia, France, Georgia, Hungary +2 more
Phase 2 Study Evaluating the Efficacy of the Combination of DKN-01 (DKK1 Inhibitor, Leap Therapeutics) and Pembrolizumab in the Treatment of Advanced or Recurrent Endometrial CancerActive Not Recruiting
NCT05761951Phase 2Updated May 19, 2026
Sponsor: M.D. Anderson Cancer Center
Endometrial Cancer
United States

Previous page Next page